Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vuk Zdinjak

Tetra Bio-Pharma Signs License Agreement With Thorne Health Tech For A Prebiotic Dietary Supplement

Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), cannabinoid-based drug developer, has signed a licensing agreement with Thorne Health Tech, Inc. (NASDAQ:THRN) for the commercialization of its patent protected prebiotic dietary supplement in the U.S. market. The agreement will include royalty on sales and milestone payments.

According to Global Marketing Insights, the prebiotics market size in the United States is expected to exceed $9.5 billion by 2027 with a strong CAGR of 9.6% in 2021.

"Thorne has an established reputation as a world leader in the sales and distribution of evidence-based supplements for consumer self-care and physician-directed therapies and Tetra is excited to partner with them to bring this product to market," said Guy Chamberland, CEO of Tetra Bio-Pharma.

Price Actions

Tetra Bio-Pharma shares closed Friday market session 10.96% lower at $0.0666 per share.

Thorne Health Tech shares closed Friday market session -2.00% lower at $4.9000 per share.

 

 

 

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.